This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Eli Lilly's proposal to acquire Orna Therapeutics sparks Australian review

( April 10, 2026, 08:08 GMT | Official Statement) -- MLex Summary: Eli Lilly and Company’s proposal to acquire 100 percent of the issued shares in Orna Therapeutics Holdings will be reviewed by Australia’s antitrust regulator. In a statement on Thursday, the Australian Competition & Consumer Commission said US-based Eli Lilly, a pharmaceutical company, discovers, develops, manufactures and markets human pharmaceutical products for various therapeutic areas, including diabetes, oncology, immunology and neuroscience. The regulator said Orna Therapeutics is a US-based early-stage biotech company developing new RNA-based treatments and delivery technologies for autoimmune diseases and cancer. The watchdog is inviting views on the acquisition until April 16.Statement follows. Questionnaire is attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections